Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.

+ Publication-Date Published in the last:

30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years

Or published in the following date range:
From (yyyy/mm/dd - month and day are optional) to ('to' is optional)
+ Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+ Sort-Order
Sort the retrieved articles by:
relevance
publication date
+ Language And with languages:

+ Species
And for:
Humans
Animals
+ Gender
And for:
Male
Female
+ Age And for these age groups:

Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years

+ Title
And for this query matching the titles:
+ Transliterated-Title
And for this query matching the title in original language:
+ Abstract
And for this query matching the abstratcs:
+ Major-Mesh
And for this query matching the MeSH-Major terms:
+ Mesh
And for this query matching any MeSH terms:
+ Journal
And for one or more of these journal abbreviated names:
OR OR
(see title abbreviations)+ Volume
And with journal volume number:
+ Issue
And with journal issue number:
+ Page
And with page number:
+ ISSN
And with ISSN:
+ Publication-Place
And with journal's country of publication:
+ Author

+ Affiliation
And with affiliation to:
+ Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior) + PMID
Show me only articles for these PMIDs (PubMed IDs):
+ Semantic-Type And with semantic types:

3. Inamoto T, Komura K, Watsuji T, Azuma H: Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.Clin Med Insights Oncol; 2011;5:101-6[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.

OBJECTIVES: To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical factors.

METHODS: A total of 176 patients with localized prostate cancer underwent HIFU therapy.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Intensity modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) are technological developments, which when applied in a model of prostate cancer, led to a significant reduction in the toxicity and digestive and urinary sequelae of 3D conformational radiotherapy.

In the absence of adaptive radiotherapy, there are many IGRT protocols and repositioning techniques, and every step in the IGRT process must be carried out with extreme rigor: installing the patient and contention system, repositioning technique with or without fiduciary markers, type of repositioning imaging, definition of margins inherent in each technique (prostate, seminal vesicles and/or pelvic lymph nodes), frequency of repositioning during treatment, dietary constraints with or without rectal lavage.

In this review, we analyzed data from the literature based on dosimetric studies and the proven clinical impact in order to answer the different questions asked by radiation oncologists at every step of the IGRT process for cancer of the prostate.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE: As transperineal interstitial permanent prostate brachytherapy (TIPPB) grows in acceptance as an option in the treatment of organ-confined prostate cancer, its associated toxicities are being defined.

This clinical report documents rectal toxicity from a large cohort of men treated by a single practitioner for adenocarcinoma of the prostate.

CONCLUSION: TIPPB is a tolerable and acceptable treatment option when used alone in early-stage, organ-confined adenocarcinoma of the prostate and in conjunction with EBRT in more advanced disease.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 10924980.001).

[ISSN] 0360-3016

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article

[Publication-country] UNITED STATES

6. Mikolajczyk SD, Rittenhouse HG: Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.Keio J Med; 2003 Jun;52(2):86-91[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.

The inactive precursor of PSA, proPSA, is associated with prostate tumors.

ProPSA is comprised of native proPSA as well as truncated proPSA forms, [-2]pPSA and [-4]pPSA, which have been shown to be more cancer-associated than native proPSA.

Free PSA in prostate cancer serum contains a median of 28% BPSA and 32% proPSA, though each form of PSA can range from 0 to more than 50% in individual samples.

Early studies revealed that proPSA significantly increases the specificity for prostate cancer, especially in the 2-4 ng/ml PSA range.

It is estimated that 20-30% of men with PSA values from 2-4 ng/ml have prostate cancer.

ProPSA represents a more cancer-specific form of PSA that better discriminates prostate cancer from BPH.

PURPOSE: To determine the impact on long-term survival from the addition of brachytherapy to external beam radiation therapy (EBRT) in patients with prostate cancer.

METHODS AND MATERIALS: Between 1992 and 1997, 104 men with cT2-3, surgically staged node-negative prostate cancer were randomized to receive either EBRT (40 Gy/20 fractions) with iridium implant (35 Gy/48 hours) or EBRT alone (66 Gy/33 fractions) to the prostate.

According to T stage, Gleason score, and prostate-specific antigen level, 60% of patients had high-risk disease.

There have been 75 deaths, including 21 from prostate cancer and 25 from second cancers.

No patients developing a second cancer have died from prostate cancer.

Similarly, there was no difference in prostate cancer-specific deaths: 9 (18%) patients in the implant arm compared with 12 (23%) in the EBRT arm (HR 0.79, 95% CI 0.34-1.87).

There was no statistically significant difference in the number of patients developing metastatic disease: 10 (20%) in the implant arm and 15 (28%) in the EBRT arm (HR 0.70, 95% CI 0.32-1.57).

CONCLUSIONS: Despite a dramatic reduction of biochemical recurrence rates, the addition of iridium implant to EBRT did not translate into improved overall survival or prostate cancer-specific survival.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.

: To compare the efficacy of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer, we conducted a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandom-E or Tandem-R assays) and digital rectal examination.

/l. or digital rectal examination was suspicious, even if transrectal ultrasonography revealed no areas suspicious for cancer.

[ISO-abbreviation] J. Urol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

10. Pellizzon AC: Interstitial high-dose-rate brachytherapy and local anesthesia for prostate cancer: a feasibility report.Curr Urol Rep; 2008 Jan;9(1):45-9[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Interstitial high-dose-rate brachytherapy and local anesthesia for prostate cancer: a feasibility report.

High-dose-rate brachytherapy (HDR-BT) to treat prostate cancer is usually performed with the patient under general or spinal anesthesia.

Eleven patients with locally advanced prostate cancer, classified as intermediate or high risk, were treated based on an institutional protocol combining HDR-BT and hypofractionated external-beam radiotherapy.

We conclude that HDR-BT for prostate cancer with the patient under local anesthesia is efficient in terms of resource use and personnel time and will facilitate and expand the use of HDR-BT at our institution and others with few beds.